CRISPR

CRISPR1-akr1a1a

ID
ZDB-CRISPR-230519-1
Name
CRISPR1-akr1a1a
Previous Names
None
Target
Sequence
5' - GGTCAGAGGATGCCAACGG - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
The PAM site was "TGG" at the 3' end.
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
zf3750 akr1a1a
Expression
Gene expression in Wild Types + CRISPR1-akr1a1a
No data available
Phenotype
Phenotype resulting from CRISPR1-akr1a1a
No data available
Phenotype of all Fish created by or utilizing CRISPR1-akr1a1a
Phenotype Fish Conditions Figures
whole organism acrolein increased amount, abnormal akr1a1azf3750/zf3750 standard conditions Fig. 1 with image from Li et al., 2026
blood glucose increased amount, abnormal akr1a1azf3750/zf3750 feeding regime Fig. 5 with image from Li et al., 2026
glucose homeostasis disrupted, abnormal akr1a1azf3750/zf3750 feeding regime Fig. 5 with image from Li et al., 2026
podocyte podocyte foot increased width, abnormal akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
whole organism glucose increased amount, abnormal akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
glucose homeostasis disrupted, abnormal akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
glomerular basement membrane increased thickness, abnormal akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
liver insrb expression decreased amount, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 4 with image from Qi et al., 2021
whole organism ab5-akt labeling decreased amount, abnormal akr1a1azf3750/zf3750; y1Tg chemical treatment by environment: acrolein Figure 7 with image from Qi et al., 2021
blood glucose increased amount, abnormal akr1a1azf3750/zf3750; y1Tg food availability Figure 4 with image from Qi et al., 2021
whole organism insrb expression decreased amount, abnormal akr1a1azf3750/zf3750; y1Tg chemical treatment by environment: acrolein Figure 6 with image from Qi et al., 2021
whole organism insra expression decreased amount, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 4 with image,  Figure 6 with image from Qi et al., 2021
whole organism ab3-akt labeling increased amount, abnormal akr1a1azf3750/zf3750; y1Tg chemical treatment by environment: acrolein Figure 7 with image from Qi et al., 2021
liver acrolein increased amount, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 4 with image from Qi et al., 2021
liver phosphofructokinase activity decreased process quality, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 4 with image from Qi et al., 2021
hyaloid vessel increased branchiness, abnormal akr1a1azf3750/zf3750; y1Tg chemical treatment by environment: acrolein Figure 6 with image from Qi et al., 2021
liver pyruvic acid decreased amount, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 4 with image from Qi et al., 2021
whole organism NADP+ biosynthetic process decreased process quality, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 1 with image,  Figure 4 with image from Qi et al., 2021
whole organism insra expression decreased amount, abnormal akr1a1azf3750/zf3750; y1Tg chemical treatment by environment: acrolein Figure 6 with image from Qi et al., 2021
whole organism ab3-akt labeling increased amount, abnormal akr1a1azf3750/zf3750; y1Tg control Figure 7 with image from Qi et al., 2021
whole organism acrolein increased amount, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 4 with image from Qi et al., 2021
glomerular basement membrane increased thickness, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 2 with image from Qi et al., 2021
whole organism ab5-akt labeling decreased amount, abnormal akr1a1azf3750/zf3750; y1Tg control Figure 7 with image from Qi et al., 2021
hyaloid vessel sprouting angiogenesis increased process quality, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 2 with image from Qi et al., 2021
hyaloid vessel increased branchiness, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 2 with image,  Figure 6 with image from Qi et al., 2021
whole organism ins expression decreased amount, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 4 with image from Qi et al., 2021
liver akr1a1a expression absent, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 1 with image from Qi et al., 2021
whole organism glucose increased amount, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 4 with image from Qi et al., 2021
whole organism insrb expression decreased amount, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 4 with image,  Figure 6 with image from Qi et al., 2021
liver insra expression decreased amount, abnormal akr1a1azf3750/zf3750; y1Tg standard conditions Figure 4 with image from Qi et al., 2021
whole organism phosphatidylinositol 3-kinase/protein kinase B signal transduction increased magnitude, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine Fig. 6 with image from Li et al., 2026
whole organism gck expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
whole organism ins expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine Fig. 6 with image from Li et al., 2026
whole organism insulin decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 6 with image from Li et al., 2026
kidney col4a4 expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
whole organism ins expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
kidney col4a3 expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
whole organism insrb expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine Fig. 6 with image from Li et al., 2026
liver arg1 expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
liver odc1 expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
glucose homeostasis disrupted, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 feeding regime Fig. 5 with image from Li et al., 2026
whole organism imidazolinone increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 2 with image from Li et al., 2026
podocyte podocyte foot increased width, exacerbated glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
whole organism glucose decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine Fig. 6 with image from Li et al., 2026
whole organism acrolein increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 1 with image from Li et al., 2026
glomerular basement membrane increased thickness, exacerbated glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
liver insrb expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
whole organism slc2a2 expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
whole organism insra expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine Fig. 6 with image from Li et al., 2026
liver arginine decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 2 with image from Li et al., 2026
kidney lamb1a expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
blood glucose increased amount, exacerbated glo1zf3029/zf3029; akr1a1azf3750/zf3750 feeding regime Fig. 5 with image from Li et al., 2026
whole organism slc2a8 expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine Fig. 6 with image from Li et al., 2026
liver asl expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
whole organism ugp2a expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine Fig. 6 with image from Li et al., 2026
whole organism phosphatidylinositol 3-kinase/protein kinase B signal transduction decreased magnitude, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 6 with image from Li et al., 2026
liver slc7a1a expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
whole organism gck expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine Fig. 6 with image from Li et al., 2026
whole organism gys1 expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
whole organism arginine decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 2 with image from Li et al., 2026
liver slc7a1b expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
liver ins expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
whole organism glucose amount, ameliorated glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine, chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester Fig. 6 with image from Li et al., 2026
kidney lama1 expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
whole organism pkmb expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
whole organism insrb expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
whole organism methylglyoxal increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 1 with image from Li et al., 2026
muscle phosphatidylinositol 3-kinase/protein kinase B signal transduction decreased magnitude, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 feeding regime Fig. 4 with image from Li et al., 2026
whole organism glucose increased amount, exacerbated glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
whole organism slc2a8 expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
liver gys1 expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
glucose homeostasis disrupted, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
liver phosphatidylinositol 3-kinase/protein kinase B signal transduction decreased magnitude, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 feeding regime Fig. 4 with image from Li et al., 2026
whole organism ugp2a expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
whole organism slc2a2 expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine Fig. 6 with image from Li et al., 2026
whole organism insulin amount, ameliorated glo1zf3029/zf3029; akr1a1azf3750/zf3750 chemical treatment by environment: arginine Fig. 6 with image from Li et al., 2026
kidney col4a5 expression increased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 5 with image from Li et al., 2026
liver ass1 expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
liver insra expression decreased amount, abnormal glo1zf3029/zf3029; akr1a1azf3750/zf3750 standard conditions Fig. 4 with image from Li et al., 2026
Citations